Merck's Phase 3 KEYNOTE-671 Trial Of Keytruda As A Perioperative Treatment Regimen For Resectable Stage II, IIIa Or IIIb Non-small Cell Lung Cancer Met Its Dual Primary Endpoint Of Overall Survival
Portfolio Pulse from Benzinga Newsdesk
Merck's Phase 3 KEYNOTE-671 trial of Keytruda, a perioperative treatment regimen for resectable stage II, IIIa or IIIb non-small cell lung cancer, has met its dual primary endpoint of overall survival.
October 10, 2023 | 10:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's successful Phase 3 trial of Keytruda could potentially boost its stock as it indicates a positive development in the company's product pipeline.
The successful trial of Keytruda indicates a positive development in Merck's product pipeline. This could potentially lead to increased revenues for the company in the future, which would likely be viewed positively by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100